Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases - Plus Therapeutics (NASDAQ:PSTV)
HOUSTON, Nov. 24, 2025 ( GLOBE NEWSWIRE ) -- Plus Therapeutics, Inc. ( Nasdaq: PSTV ) ( the "Company" ) , a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system ( CNS ) cancers, announced it has completed a Type B meeting ...
How this was made

The 30-second read
Why it matters
Successful FDA meetings can expedite clinical pathways, positively influencing stock valuation.
Market read
This milestone is relevant for biotech investors focusing on CNS cancer treatments.
What to watch
Clinical trial results and broader market conditions could influence stock performance more than regulatory news alone.
Background
Plus Therapeutics is advancing therapies for CNS cancers, with recent FDA interactions being critical for future development.
Ticker impact
The news pertains directly to Plus Therapeutics, Inc. (PSTV), a biotech company developing treatments for CNS cancers, including recent FDA meeting outcomes.
Moderate upward price movement expected over the next 1-3 months.
The completion of a key FDA meeting is a significant milestone, but market reaction depends on subsequent clinical data and regulatory decisions.
Market effects
Potential positive sentiment in biotech and CNS cancer treatment sectors.
Limited regional impact, primarily affecting US biotech stocks.
Low; specific to US regulatory developments.
Counterpoint
Market may have already priced in this milestone; potential for profit-taking or volatility if subsequent data is disappointing.
Key entities
- CompanyPlus Therapeutics, Inc.
Biotech company focusing on CNS cancer diagnostics and therapeutics.
- Regulatory AgencyFDA
U.S. Food and Drug Administration, overseeing drug approvals.



